Can Dogs Become the First Regulated Longevity Market?
Use canine lifespan-extension trials as a regulatory test case for longevity medicine. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Trials
Resilience Endpoints: Why Recovery May Matter More Than Biological Age
Vaccine response, post-surgery recovery, infection recovery, exercise adaptation, and stress-response tests as practical geroscience endpoints. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Why Negative Longevity Trials Matter More Than the Field Admits
Failed or mixed trials define endpoints, populations, dosing, mechanisms, and claim boundaries. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
What the DO-HEALTH Omega-3 Trial Actually Showed About Slowing Biological Aging
The DO-HEALTH omega-3 paper became one of those longevity studies that was easy to summarize too quickly. A daily gram
Why Longevity Trials Struggle With Endpoints — and What Researchers Are Using Instead
The most seductive endpoint in longevity science is also the least practical one: living longer. In mice, that is manageable.